- Home
- EWTX vs INTR Comparison
EWTX vs INTR Comparison
Compare EWTX & INTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EWTX | INTR |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EWTX | INTR |
|---|---|---|
| Price | $33.86 | $8.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $39.00 | $10.00 |
| AVG Volume (30 Days) | 746.3K | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $84.07 |
| Revenue Next Year | N/A | $18.26 |
| P/E Ratio | ★ N/A | $16.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.31 | $6.13 |
| 52 Week High | $35.00 | $10.36 |
Technical Indicators
Market Signals| Indicator | EWTX | INTR |
|---|---|---|
| Relative Strength Index (RSI) | 60.61 | 49.68 |
| Support Level | $28.72 | $7.77 |
| Resistance Level | N/A | $8.64 |
| Average True Range (ATR) | 1.48 | 0.35 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 79.66 | 56.96 |
Price Performance
Historical ComparisonAbout EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.